United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/06/2025 BST			5-day change	1st Jan Change
283.35 ^USD	-0.98%		-13.03%	-19.69%

06-10	Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	MT
06-10	Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	RE

Morgan Stanley Downgrades United Therapeutics to Equalweight From Overweight, Adjusts PT to $321 From $310

Published on 11/07/2024 at 11:53, updated on 11/07/2024 at 12:16

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about United Therapeutics Corporation

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	06-10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	06-10	MT
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	06-02	MT
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
United Therapeutics Corporation, Q1 2025 Earnings Call, Apr 30, 2025	04-30
United Therapeutics Q1 Earnings, Revenue Rise	04-30	MT
Earnings Flash (UTHR) United Therapeutics Posts Q1 Revenue $794.4M, vs. FactSet Est of $729.3M	04-30	MT
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
United Therapeutics Enters Credit Agreement With Wells Fargo - SEC Filing	04-28	RE
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility	04-28	CI
Liquidia Corp Unit Files Patent Infringement Action Against United Therapeutics	04-22	RE
BofA Securities Upgrades United Therapeutics to Neutral From Underperform	04-21	MT
United Therapeutics Insider Sold Shares Worth $3,121,543, According to a Recent SEC Filing	04-21	MT
United Therapeutics Insider Sold Shares Worth $1,138,200, According to a Recent SEC Filing	04-08	MT
United Therapeutics Insider Sold Shares Worth $3,367,984, According to a Recent SEC Filing	04-07	MT
United Therapeutics Insider Sold Shares Worth $796,991, According to a Recent SEC Filing	03-25	MT
UBS Adjusts Price Target on United Therapeutics to $410 From $440, Maintains Buy Rating	03-18	MT
United Therapeutics Corporation Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 10:00 AM	03-11
United Therapeutics Corporation Presents at TD Cowen 45th Annual Healthcare Conference, Mar-03-2025 01:50 PM	03-03
Stocks in motion: Intuit and Axon rise on great results, Applovin tumbles on short-seller attack	02-26
Correction: United Therapeutics Q4 Net Income, Revenue Rise	02-26	MT

Chart United Therapeutics Corporation

Duration

Period

UTHR: Dynamic Chart

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,305

Sector

Pharmaceuticals

Calendar

06-26 - Annual General Meeting

More about the company